Plecanatide
- Generic Name
- Plecanatide
- Brand Names
- Trulance
- Drug Type
- Small Molecule
- Chemical Formula
- C65H104N18O26S4
- CAS Number
- 467426-54-6
- Unique Ingredient Identifier
- 7IK8Z952OK
- Background
Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age
- Indication
Plecanatide is indicated for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adult patients.
- Associated Conditions
- Irritable Bowel Syndrome With Constipation (IBS-C), Chronic idiopathic constipation (CIC)
- Associated Therapies
- -
GCC Agonist Signal in the Small Intestine
- Conditions
- Malignant Digestive System NeoplasmBarrett EsophagusGastroesophageal Reflux Disease
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: EsophagogastroduodenoscopyDrug: LinaclotideDrug: Plecanatide
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 43
- Registration Number
- NCT05107219
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.